Effect Of Semaglutide In Coronary Atheroma Plaque

Sponsor
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
Study ID
NCT05071417
Phase
PHASE3
Status
Unknown

Conditions

  • Atheroscleroses, Coronary

Eligibility Criteria

Sex
ALL
Age
35 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide — DRUG
    Usual treatment with semaglutide. Dose 0.5 - 1mg weekly, subcutaneous, weekly

Study Details

The main objective of this trial is to evaluate the effect of Semaglutide on the burden of coronary atherosclerosis, based on the change in Percent Atheroma Volume (PAV) by quantifying atheroma plaque throughout the coronary tree based on the analysis of CCTA in asymptomatic subjects with T2D in optimized and stable treatment with Semaglutide.

Key Dates

Start date
Nov 30, 2021
Status verified
Sep 2021
Primary completion
Dec 31, 2024
Completion
Dec 31, 2025

Study Design

Enrollment
120 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Semaglutide
    Patients on semaglutide

Primary Outcome Measure

Plaque burden modification assessed by coronary CT and plaque quantification [ Time Frame: 18 months ]

Central Contacts